³ΙΘΛΏμΚΦ

header-logo
GettyImages-609179959-hero
headshot

Binod Dhakal, MD

Professor

view provider profile

Locations

  • Froedtert Hospital
  • Clinical Cancer Center - Froedtert Hospital

Specialties

  • Hematology
  • Medical Oncology

Languages

  • English, Nepali, Hindi

Clinical Cancer Center - Froedtert Hospital

Education

  • MD - Doctor of Medicine

Biography

Binod Dhakal, MD, MS, is Assistant Professor of Medicine, at the ³ΙΘΛΏμΚΦ, Division of Hematology, specializing in multiple myeloma and plasma cell disorders. He graduated from Manipal College of Medical Sciences, Pokhara Nepal in 2004, completed Internal Medicine Residency at Saint Francis Hospital Evanston Illinois, and a fellowship in hematology/oncology at the ³ΙΘΛΏμΚΦ, where he also served as a Chief Fellow. Prior to joining the fellowship, he was Assistant Professor of Medicine at the Medical College in Wisconsin in the Division of General Internal Medicine. He has authored numerous publications, including journal articles, meeting abstracts and book chapters. He has also won several awards during his fellowship which include the American Society of Clinical Oncology (ASCO) Merit Award; ³ΙΘΛΏμΚΦ Affiliated Hospitals (³ΙΘΛΏμΚΦAH) research award; Central Society for Clinical and Translational Research (CSCTR) best oral abstract and travel trainee award; American Society for Blood and Marrow Transplantation (ASBMT) clinical research training course; and, Outstanding Medical School Teacher award. Additionally, he was the recipient of the Mazie Froedtert Willms and Sue Froedtert Cancer Scholarship, and obtained his Master’s Degree in Clinical and Translational Science.

Research Interests

Dr. Dhakal's current research interests focus on novel drug treatments for patients with multiple myeloma and related plasma cell disorders by designing and conducting early phase clinical trials.

Publications

  • (Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM.) Future Oncol. 2026 Oct 12:1-12 PMID: 42860893 10/12/2026

  • (Dholaria BR, Medvedova E, Ravi G, Dhakal B, Callander NS, Godby KN, Bal S, Schmidt T, Silbermann RW, Costa LJ.) Leukemia. 2026 Oct 06 PMID: 42839068 SCOPUS ID: 2-s2.0-105052797755 10/07/2026

  • (Mian H, Faisal MS, Chen T, Brazauskas R, Oloyede T, Ahmed N, Afrough A, Anderson LD, Banerjee R, Berdeja J, Bidikian A, Devos J, Dhakal B, Dias A, Dima D, Efebera YA, Gowda L, Hansen DK, Hashmi H, Landau HJ, Lekakis L, Mirza AS, Narra R, Patel K, Rosko AE, Schroeder M, Sidana S, Usmani S, Pasquini MC, Nishihori T, Akhtar OS, Mohan M.) Cancer. 2026 Oct 01;132(19):e70614 PMID: 42779338 PMCID: PMC13601916 SCOPUS ID: 2-s2.0-105051458471 09/24/2026

  • (Frigault MJ, Dhakal B, Jakubowiak AJ, Raje N, Banerjee K, Mu CJ, Hart KC, Shachar S, Andrews LP, Cheung LS, Griffin FM, Witter AR, Hyde M, Pham C, Gandra N, Shakya T, Rajan B, Cortesio C, Haile ST, Nowyhed H, Nair-Gupta P, Mitra P, Chan RJ, Kostic A, Heery CR, Rosenblatt J, Bishop MR.) N Engl J Med. 2026 Sep 24;395(12):1180-1192 PMID: 42777241 SCOPUS ID: 2-s2.0-105051457977 09/23/2026

  • (Han J, Liu SH, Arsang-Jang S, Xu Z, Rentscher KE, Mathison AJ, Tschannen M, Sun F, Auer PL, Kerns S, Hari P, Dhakal B, Janz S, Jin VX, Urrutia R, D'souza A, Dong J.) Cells. 2026 Sep 22;15(19) PMID: 42882420 PMCID: PMC13663980 10/16/2026

  • (Mina R, Terpos E, Cani L, Nooka A, Trudel S, Voorhees P, Mian H, Dhakal B, Usmani S, Richter J, Popat R, Mateos MV, Lonial S.) Clin Lymphoma Myeloma Leuk. 2026 Sep;26(9):609-622 PMID: 42521571 SCOPUS ID: 2-s2.0-105045758260 07/29/2026

  • (Hansen DK, Dima D, Mian H, Devos J, Brazauskas R, Oloyede T, Afrough A, Ahmed N, Anderson LD Jr, Banerjee R, Berdeja JG, Bidikian A, Dhakal B, Dias A, Efebera Y, Faisal MS, Gowda L, Hashmi H, Mirza AS, Mohan M, Narra R, Rosko AE, Schroeder M, Nishihori T, Landau H, Usmani S, Pasquini MC, Akhtar OS, Sidana S, Patel KK.) Blood Cancer J. 2026 Aug 31;16(1) PMID: 42675051 PMCID: PMC13530125 SCOPUS ID: 2-s2.0-105048913700 09/01/2026

  • (Gundroo HM, Nasrollahi E, Alford B, Dhakal B, Narra R, D'Souza A, Mhaskar R, Akhtar OS.) Br J Haematol. 2026 Aug 30 PMID: 42669956 SCOPUS ID: 2-s2.0-105048847765 08/31/2026

  • (Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, Godby KN, Bal S, Huls F, Silbermann RW, Costa LJ.) Cancer. 2026 Jul 15;132(14):e70478 PMID: 42473325 PMCID: PMC13382204 SCOPUS ID: 2-s2.0-105045095041 07/20/2026

  • (Rodríguez-Otero P, Gállego Pérez-Larraya J, Lin Y, Dietrich J, van de Donk NWCJ, Mason XL, Dhakal B, Jakubowiak AJ, Lendvai N, Li H, Yeh TM, Lee E, Marquez L, Sharma M, Montes de Oca R, Wang F, Plaks V, Henry K, Taraseviciute A, Jethava Y, Jablow L, Afifi S, De Braganca KC, Madduri D, Zhu J, Koneru M, Akram M, Patel N, Cohen AD, Santomasso BD.) Clin Lymphoma Myeloma Leuk. 2026 Jul;26(7):423-435.e3 PMID: 42161729 SCOPUS ID: 2-s2.0-105038969304 05/21/2026

  • (Vega G, Morillo D, Riedhammer C, Smits F, Bag A, Julian K, Gomis NT, Gaisan CM, Bermudez MA, Shah MR, Mohyuddin GR, Dhakal B, Rasche L, Schinke C, D'Souza A, Szabo A, van de Donk NWCJ, Chakraborty R, Mohan M.) Hemasphere. 2026 Jun;10(6):e70396 PMID: 42261378 PMCID: PMC13242627 06/09/2026

  • (Susanibar-Adaniya S, Derman BA, Cohen AD, Vogl DT, Richard S, Rossi A, Frigualt MJ, Yee AJ, Dhakal B, Bar N.) Blood Cancer J. 2026 Apr 28;16(1) PMID: 42049698 PMCID: PMC13125467 SCOPUS ID: 2-s2.0-105037218527 04/29/2026

Publications of from the

© 2026 ³ΙΘΛΏμΚΦ.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination, Anti-Harassment, and Legal Compliance Statement
The ³ΙΘΛΏμΚΦ (³ΙΘΛΏμΚΦ) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, military status, or other legally protected classification. ³ΙΘΛΏμΚΦ maintains full compliance with all applicable federal, state, and local laws and regulations in pursuit of our missions. Consistent with federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making.

³ΙΘΛΏμΚΦ's policies, federal and state laws, and regulations prohibit unlawful discrimination and harassment. Employees, learners, students, applicants, or other members of the ³ΙΘΛΏμΚΦ community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic.